Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2018

Open Access 01-12-2018 | Research article

Geographic Variations and Time Trends in Cancer Treatments in Taiwan

Authors: Jason C. Hsu, Sheng-Mao Chang, Christine Y. Lu

Published in: BMC Public Health | Issue 1/2018

Login to get access

Abstract

Background

Targeted therapies have become important treatment options for cancer care in many countries. This study aimed to examine recent trends in utilization of antineoplastic drugs, particularly the use of targeted therapies for treatment of cancer, by geographic region in Taiwan (northern, midwestern, southern, and eastern regions and the outer islands).

Methods

This was a retrospective observational study of antineoplastic agents using 2009-2012 quarterly claims data from Taiwan’s National Health Insurance Research Database. Yearly market shares by prescription volume and costs for targeted therapies among total antineoplastic agents by region were estimated. We used multivariate regression model and ANOVA to examine variations in utilization of targeted therapies between geographic regions and used ARIMA models to estimate longitudinal trends.

Results

Population-adjusted use and costs of antineoplastic drugs (including targeted therapies) were highest in the southern region of Taiwan and lowest in the outer islands. We found a 4-fold difference in use of antineoplastic drugs and a 49-fold difference in use of targeted therapies between regions if the outer islands were included. There were minimal differences in use of antineoplastic drugs between other regions with about a 2-fold difference in use of targeted therapies. Without considering the outer islands, the market share by prescription volume and costs of targeted therapies increased almost 2-fold (1.84-1.90) and 1.5-fold (1.26-1.61) respectively between 2009 and 2012. Furthermore, region was not significantly associated with use of antineoplastic agents or use of targeted therapies after adjusting for confounders. Region was associated with costs of antineoplastic agents but it was not associated with costs of targeted therapies after confounding adjustments.

Conclusions

Use of antineoplastic drugs overall and use of targeted therapies for treatment of cancer varied somewhat between regions in Taiwan; use was notably low in the outer islands. Strategies might be needed to ensure access to cancer care in each region as economic burden of cancer care increase due to growing use of targeted therapies.
Appendix
Available only for authorised users
Literature
1.
Dranitsaris G, Truter I, Lubbe MS, Amir E, Evans W. Advances in cancer therapeutics and patient access to new drugs. Pharmacoeconomics. 2011;29:213–24.CrossRefPubMed
2.
Schoenlein PV, Hou M, Samaddar JS, et al. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol. 2007;31:643–55.PubMed
3.
Hou N, Huo D. A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase. Breast Cancer Res Treat. 2013;138:633–41.CrossRefPubMed
4.
Horowitz NS, Miller A, Rungruang B, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33:937–43.CrossRefPubMedPubMedCentral
5.
Lippman ME, Krueger KA, Eckert S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol. 2001;19:3111–6.CrossRefPubMed
6.
7.
Fedewa SA, Sauer AG, Siegel RL, Jemal A. Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2015;24:637–52.CrossRefPubMed
8.
Perdue DG, Haverkamp D, Perkins C, Daley CM, Provost E. Geographic variation in colorectal cancer incidence and mortality, age of onset, and stage at diagnosis among American Indian and Alaska Native people, 1990-2009. Am J Public Health. 2014;104(Suppl 3):S404–14.CrossRefPubMedPubMedCentral
9.
Steliarova-Foucher E, Stiller C, Kaatsch P, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet. 2004;364:2097–105.CrossRefPubMed
10.
Ess S, Savidan A, Frick H, et al. Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol. 2010;34:116–21.CrossRefPubMed
11.
Christian WJ, Huang B, Rinehart J, Hopenhayn C. Exploring geographic variation in lung cancer incidence in Kentucky using a spatial scan statistic: elevated risk in the Appalachian coal-mining region. Public Health Rep. 2011;126:789–96.CrossRefPubMedPubMedCentral
12.
Lai SM, Zhang KB, Uhler RJ, Harrison JN, Clutter GG, Williams MA. Geographic variation in the incidence of colorectal cancer in the United States, 1998-2001. Cancer. 2006;107:1172–80.CrossRefPubMed
13.
Chiou ST, Lu TH. Changes in geographic variation in the uptake of cervical cancer screening in Taiwan: possible effects of "leadership style factor"? Health Policy. 2014;114:64–70.CrossRefPubMed
14.
Smieliauskas F, MacMahon H, Salgia R, Shih YC. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. J Med Screen. 2014;21:207–15.CrossRefPubMedPubMedCentral
15.
Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer. 2006;119:1946–52.CrossRefPubMed
16.
McWilliams JM, Dalton JB, Landrum MB, Frakt AB, Pizer SD, Keating NL. Geographic variation in cancer-related imaging: Veterans Affairs health care system versus Medicare. Ann Intern Med. 2014;161:794–802.CrossRefPubMedPubMedCentral
17.
Su WW, Chen CH, Lin HH, et al. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. Hepatol Int. 2009;3:537–43.CrossRefPubMedPubMedCentral
18.
Guadagnolo BA, Liu CC, Cormier JN, Du XL. Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. Cancer. 2010;116:3505–12.CrossRefPubMed
19.
Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. 2015;18:149–54.CrossRefPubMedPubMedCentral
20.
Deleyiannis FW, Weymuller EA Jr, Garcia I, Potosky AL. Geographic variation in the utilization of esophagoscopy and bronchoscopy in head and neck cancer. Arch Otolaryngol Head Neck Surg. 1997;123:1203–10.CrossRefPubMed
21.
Reames BN, Sheetz KH, Waits SA, Dimick JB, Regenbogen SE. Geographic variation in use of laparoscopic colectomy for colon cancer. J Clin Oncol. 2014;32:3667–72.CrossRefPubMedPubMedCentral
22.
Chen CH, Su WW, Yang SS, et al. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. J Gastroenterol Hepatol. 2006;21:1561–6.CrossRefPubMed
23.
Andia ME, Hsing AW, Andreotti G, Ferreccio C. Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study. Int J Cancer. 2008;123:1411–6.CrossRefPubMedPubMedCentral
24.
Kohne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009;14:478–88.CrossRefPubMed
25.
Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Curr Probl Cancer. 2009;33:73–111.CrossRefPubMed
26.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.CrossRefPubMed
27.
Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist. 2015;20:400–10.CrossRefPubMedPubMedCentral
28.
Biswas B. Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer in the era of personalized medicine. J Clin Oncol. 2015;33:524.CrossRefPubMed
29.
Song Z, Zhang Y. Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer. Arch Med Sci. 2015;11:164–8.CrossRefPubMed
30.
Lu CY, Srasuebkul P, Drew AK, Chen K, Ward RL, Pearson SA. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? Breast. 2013;22:482–7.CrossRefPubMed
31.
Lu CY, Srasuebkul P, Drew AK, Ward RL, Pearson SA. Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. Intern Med J. 2012;42:1229–35.CrossRefPubMed
32.
33.
Hsu JC, Lu CY. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study. BMJ Open. 2016;6:e011322.CrossRefPubMedPubMedCentral
34.
Hsu JC, Gonzalez-Gonzalez LA, Lu VH, Lu CY. Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan. BMJ Open. 2016;6:e010706.CrossRefPubMedPubMedCentral
35.
Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly. Med Care. 2003;41:1331–42.CrossRefPubMed
36.
Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: An interrupted time series study. Health Policy. 2013;
37.
Hsu JC, Ross-Degnan D, Wagner AK, et al. Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies. J Pharm Policy Pract. 2015;8:15.CrossRefPubMedPubMedCentral
38.
39.
Report CRA. Taiwan. Health Promotion Administration. Ministry of Health and Welfare. 2011;2014
40.
Mills TC. Time Series Techniques for Economists. Cambridge University Press. 1990;
41.
Asteriou DH, Stephen G. ARIMA Models and the Box–Jenkins Methodology, Applied Econometrics (Second ed.) Palgrave MacMillan 2011:265-86.
42.
Domenighetti G, Casabianca A. Health care economics, uncertainty and physician-induced demand. Schweiz Med Wochenschr. 1995;125:1969–79.PubMed
43.
Mullins RJ, Clark S, Camargo CA Jr. Regional variation in infant hypoallergenic formula prescriptions in Australia. Pediatr Allergy Immunol. 2010;21:e413–20.CrossRefPubMed
44.
Kreng VB, Yang CT. The equality of resource allocation in health care under the National Health Insurance System in Taiwan. Health Policy. 2011;100:203–10.CrossRefPubMed
45.
46.
Wahlstera P, Scahillb S, Lu CY, Babar Z-U-D. Barriers to access and use of high cost medicines: A review. Health Policy and Technology. 2015;4:191–214.CrossRef
47.
48.
49.
Hall WD, Ward R, Liauw WS, Lu CY, Brien JA. Tailoring access to high cost, genetically targeted drugs. Med J Aust. 2005;182:607–8.PubMed
50.
Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8:77–94.CrossRefPubMed
51.
Metadata
Title
Geographic Variations and Time Trends in Cancer Treatments in Taiwan
Authors
Jason C. Hsu
Sheng-Mao Chang
Christine Y. Lu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2018
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-017-4615-y

Other articles of this Issue 1/2018

BMC Public Health 1/2018 Go to the issue

Research article

Stress begets stress: the association of adverse childhood experiences with psychological distress in the presence of adult life stress

Correction

Correction to: “His mind will work better with both of us”: a qualitative study on fathers’ roles and coparenting of young children in rural Pakistan

Research article

Epidemiology of birth defects based on surveillance data from 2011–2015 in Guangxi, China: comparison across five major ethnic groups

Research article

Does coffee drinking have beneficial effects on bone health of Taiwanese adults? A longitudinal study

Research article

Determinants of illness-specific social support and its relation to distress in long-term melanoma survivors

Research article

Water insecurity and gendered risk for depression in rural Uganda: a hotspot analysis